• Home
  • About
    • About I-MAK
    • Our Work
    • I-Mak Directors
    • Board Of Directors
    • Advisory Board
    • Partners
    • Contact
  • Our Cases
    • Our Cases
    • FAQs
    • Lopinavir/Ritonavir
    • Abacavir Sulfate
    • Nevirapine Hemihydrate
    • Oseltamivir
    • Tenofovir
  • Testimonials
  • Media Center
    • Video/Audio
    • News Releases
    • Media Articles
    • Bios & Photos
  • Resources
    • I-MAK Blog
    • Archive
    • Publications
    • Presentations
    • Patent Landscapes
    • Pharmaceutical Patent Decisions
    • Patent Information & Databases
    • IP & Health Links
  • Donate

I-MAK

Initiative For Medicines, Access & Knowledge
  • Home
  • About
    • About I-MAK
    • Our Work
    • I-Mak Directors
    • Board Of Directors
    • Advisory Board
    • Partners
    • Contact
  • Our Cases
    • Our Cases
    • FAQs
    • Lopinavir/Ritonavir
    • Abacavir Sulfate
    • Nevirapine Hemihydrate
    • Oseltamivir
    • Tenofovir
  • Testimonials
  • Media Center
    • Video/Audio
    • News Releases
    • Media Articles
    • Bios & Photos
  • Resources
    • I-MAK Blog
    • Archive
    • Publications
    • Presentations
    • Patent Landscapes
    • Pharmaceutical Patent Decisions
    • Patent Information & Databases
    • IP & Health Links
  • Donate

  • Home
  • About
    • About I-MAK
    • Our Work
    • I-Mak Directors
    • Board Of Directors
    • Advisory Board
    • Partners
    • Contact
  • Our Cases
    • Our Cases
    • FAQs
    • Lopinavir/Ritonavir
    • Abacavir Sulfate
    • Nevirapine Hemihydrate
    • Oseltamivir
    • Tenofovir
  • Testimonials
  • Media Center
    • Video/Audio
    • News Releases
    • Media Articles
    • Bios & Photos
  • Resources
    • I-MAK Blog
    • Archive
    • Publications
    • Presentations
    • Patent Landscapes
    • Pharmaceutical Patent Decisions
    • Patent Information & Databases
    • IP & Health Links
  • Donate
Search

 

Subscribe Via RSS

 

Or Email

Enter your email address:

Delivered by FeedBurner

 

« Abbott Patent Application for HIV Spurned | Main | When Medical Patents Weaken Health Care »
Monday
Jan032011

India Rejects HIV Drug Application By Abbott Laboratories

DateMonday, January 3, 2011 at 9:12PM

India, over the New Year weekend, has rejected an unmerited HIV drug patent application by US drug giant Abbott Laboratories, paving the way for access to lifesaving medication for HIV patients across the world. Read full story here.

AuthorI-Mak | Comments Off | Share ArticleShare Article
Except for publications commissioned or published by third parties all content on this site is licensed under a Creative Commons Attribution 3.0 License